共 50 条
- [41] Phase II Study of Irinotecan Plus Panitumumab as Second-Line Therapy for Patients with Advanced Esophageal AdenocarcinomaONCOLOGIST, 2018, 23 (09): : 1004 - +Yoon, HarryKarapetyan, LilitChoudhary, AnitaKosozi, RamlaBali, Gurvinder SinghZaidi, Ali H.Atasoy, AjlanForastiere, Arlene A.Gibson, Michael K.
- [42] EGF20003: A single arm, multicentre, open-label phase II study of orally administered lapatinib (GW572016) as single-agent, second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: final analysisANNALS OF ONCOLOGY, 2004, 15 : 111 - 111Wuelfing, ChristianMachiels, Jean-PascalRichel, DirkGrimm, Marc-OliverTreiber, Uwede Groot, MarcoBeuzeboc, PhilippeFarrell, JohnColman, JessicaEl-Hariry, Iman
- [43] Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trialLANCET ONCOLOGY, 2020, 21 (08): : 1057 - 1065Kawazoe, AkihitoFukuoka, ShotaNakamura, YoshiakiKuboki, YasutoshiWakabayashi, MasashiNomura, ShogoMikamoto, YuichiShima, HikariFujishiro, NorikoHiguchi, TsukikoSato, AkihiroKuwata, TakeshiShitara, Kohei
- [44] Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16107 - E16107Zhao, KuaileKim, Sung-BaeKato, KenHsu, Chih-HungHu, ShengWang, FengKojima, TakashiKim, Young SaingVan Cutsem, EricAjani, Jaffer A.Li, LiyunDing, NingningTao, AiyangShen, Lin
- [45] KEYNOTE-119: A randomized phase III study of single-agent pembrolizumab (MK-3475) vs single-agent chemotherapy per physician's choice for metastatic triple-negative breast cancer (mTNBC).JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Winer, Eric P.Dang, ThaoKarantza, VassilikiSu, Shu-Chih
- [46] A single-arm, multicenter, open-label phase II trial of cabazitaxel as second-line treatment for patients with locally advanced or metastatic transitional cell carcinoma (TCC)JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)Peer, AvivitNeumann, AvivitKeizrnan, DanielFrank, Stephen JayBerger, RaananLeitzin, LarisaPinto, EsterNeiman, VictoriaRosenbaum, Eli
- [47] A single-arm, multicenter, open-label phase II trial of cabazitaxel as second-line treatment for patients with locally advanced or metastatic transitional cell carcinoma (TCC).JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Peer, AvivitNeumann, AvivitKeizman, DanielFrank, Stephen JayBerger, RaananLeitzin, LarisaPinto, EsterNeiman, VictoriaRosenbaum, Eli
- [48] KEYNOTE-062:Phase 3 study of pembrolizumab alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Tabernero, JosepBang, Yung-JueFuchs, Charles S.Ohtsu, AtsushiKher, UmaLam, BaohoangKoshiji, MinoriVan Cutsem, Eric
- [49] Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 studyLANCET, 2019, 394 (10212): : 1915 - 1928Burtness, BarbaraHarrington, Kevin J.Greil, RichardSoulieres, DenisTahara, Makotode Castro, Gilberto, Jr.Psyrri, AmandaBaste, NeusNeupane, PrakashBratland, AseFuereder, ThorstenHughes, Brett G. M.Mesia, RicardNgamphaiboon, NuttapongRordorf, TamaraIshak, Wan Zamaniah WanHong, Ruey-LongMendoza, Rene GonzalezRoy, AnanyaZhang, YayanGumuscu, BurakCheng, Jonathan D.Jin, FanRischin, Danny
- [50] An Open-label, Single-arm, Phase 2 Trial of Panitumumab Plus FOLFIRI as Second-line Therapy in Patients with Metastatic Colorectal CancerCLINICAL COLORECTAL CANCER, 2011, 10 (03) : 171 - 177Cohn, Allen L.Shumaker, Grace C.Khandelwal, PankajSmith, David A.Neubauer, Marcus A.Mehta, NileshRichards, DonaldWatkins, David L.Zhang, KathyYassine, Mohamed R.